Drug Trial Radar · NCT04224987
Azithromycin for Child Survival in Niger: Mortality and Resistance Trial
Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
864,493
Actual
Start
Nov 24, 2020
Primary completion
Jul 31, 2024
Study completion Jul 31, 2024
Sponsor
- Lead sponsor
- University of California, San FranciscoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bill and Melinda Gates Foundation; Ministry of Health, Niger
- First posted
- Jan 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 month, up to 59 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The MORDOR trial found that biannual distribution of azithromycin to children 1-59 months old reduced child mortality. The World Health Organization (WHO) released conditional guidelines for this intervention, which include targeting azithromycin distributions to children 1-11 months of age in high mortality settings.Targeting treatment to children 1-11 months old could reduce antimicrobial resistance by limiting antibiotic distributions while treating children at the highest mortality risk. However, this targeted intervention has not yet been tested. The AVENIR mortality/resistance trial aims to assess the efficacy of age-based targeting of biannual azithromycin distribution on mortality as well as determine the impact of age-based targeting on antimicrobial resistance.
Conditions
- Mortality
- Resistance Bacterial
- Child, Only
Interventions
AzithromycinDrug
Azithromycin will be administered as a directly observed dose in oral suspension form for children: 1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g) 2. For children 1-11 months of age, weight or age-based dosing will be used 3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program
PlaceboOther
Placebo will be administered as a directly observed dose in oral suspension form for children: 1. Single-dose of 20mg/kg in children (up to the maximum adult dose of 1g) 2. For children 1-11 months of age, weight-based dosing will be used 3. For children 12-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause Mortality (1-59 Months Old)Time frame: from 6 months up to 2.5 years
- All-cause Mortality (1-11 Months Old)Time frame: from 6 months up to 2.5 years
- All-cause Mortality (12-59 Months Old)Time frame: from 6 months up to 2.5 years
- Prevalence of Resistance to Macrolides - Nasopharyngeal Swabs (1-59 Months Old)Time frame: After 4 distributions (approximately 24 months)
- Load of Genetic Determinants of Resistance to Macrolides - Rectal Swabs (1-59 Months Old)Time frame: After 4 distributions (approximately 24 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Programme national de santé oculaire
Niamey, Niger
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.